Scientists hunt for clues to predict liver cancer drug response
NCT ID NCT05197504
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study analyzed tumor and blood samples from 166 people with advanced liver cancer who received a combination of atezolizumab and bevacizumab. The goal was to find biomarkers—biological clues—that could predict how well a patient responds to treatment and how long they survive. Researchers used advanced genetic and molecular techniques to better understand the disease and identify potential new treatment targets.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab plus bevacizumab
What this could lead to
If successful, this could help identify which patients are most likely to benefit from this drug combination, leading to more personalized treatment for advanced liver cancer.
What could go wrong
This is an observational biomarker study, not a treatment trial. It may not find clear or useful biomarkers, and results may not change clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea